drugset
Drugs / Kanglaite Injection
last change May 2022 re-read 2 minutes ago

Kanglaite Injection

also known as KLTi
Developed for
non-small cell lung carcinoma
Investigated by
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences · Jie Li · Ministry of Science and Technology of the People´s Republic of China

Trials 1 · a red edge is where a trial was stopped

today NCT03986528 · Ph 4
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT03986528 Aug 2019 → Mar 2022 non-small cell lung carcinoma Jie Li Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Kanglaite Injection ClinicalTrials.gov intervention name — accepted as the source's own label NCT03986528 ↗
Known as KLTi “Kanglaite injections (KLTi) have been widely used for the treatment of cancer in China.” PMID 33731199 ↗ Mar 2021
Route Intravenous “Kanglaite injection 200ml by IV infusion” NCT03986528 ↗